2024 Archives

Optimization of Prostate Biopsy – Micro-Ultrasound versus MRI (OPTIMUM)

Laurence Klotz, MD, FRCSC | Nov 2024

Laurence Klotz, MD, FRCSC, introduces the OPTIMUM trial, a landmark international study comparing micro-ultrasound and MRI for prostate cancer detection. In this 9-minute presentation, Dr. Klotz explains that micro-ultrasound, operating at 29 MHz, offers three times greater resolution than conventional ultrasound. Using a PRIMUS scoring system analogous to PI-RADS, micro-ultrasound demonstrates its utility in identifying highly sensitive lesions.

Dr. Klotz details the trial’s three-arm design, which involves MRI with conventional ultrasound, MRI with micro-ultrasound, and micro-ultrasound alone to assess non-inferiority and complementary detection capabilities.

Dr. Klotz emphasizes the trial’s importance for minimizing bias and improving diagnostic practices, particularly given its potential to replace or complement MRI. He highlights the study’s robust design, comprehensive objectives, and international collaboration, anticipating its transformative impact on prostate cancer diagnosis and management.

MRI PI-RADS Standardization and Clinical Evaluation

Clare Tempany, MB, BCh, BAO | Nov 2024

Clare Tempany, MB, BCh, BAO, Harvard Medical School, addresses the standardization and clinical evaluation of PI-RADS, a key tool in prostate cancer imaging. In her 13-minute presentation, Dr. Tempany begins by tracing the history of the RADS program, emphasizing its role in reducing variability and improving communication in radiological reporting. She highlights the utility of prostate MRI, focusing on its capacity to aid in detection, characterization, and targeted biopsies for clinically significant cancers.

Dr. Tempany reviews the PI-RADS v2.1 updates, which refine imaging protocols and stress the inclusion of previously overlooked areas like the anterior fibromuscular stroma. She provides examples to illustrate how these improvements enhance lesion detection and biopsy targeting. While discussing the growing interest in bi-parametric MRI, Dr. Tempany remains cautious, advocating for multiparametric MRI in most cases due to its added value for less experienced readers or in challenging cases.

She highlights the global shift toward recommending MRI before biopsy, citing changes in major guidelines and increased adoption rates. Dr. Tempany underscores the ongoing efforts to enhance MRI quality and interpretation, focusing on integrating AI for future improvements.

Optimizing MRI Techniques for Prostate Cancer Diagnosis

Fergus Coakley, MD | Nov 2024

Fergus Coakley, MD, Portland Health and Science University, Portland, Oregon, delivers a 10-minute presentation on optimizing MRI for prostate cancer diagnosis, addressing key shifts in diagnostic paradigms. He explains the transition from systematic biopsies following PSA screening to a targeted approach using multiparametric MRI (mpMRI) and in-bore biopsies. He highlights the superior signal-to-noise ratio of endorectal coils, emphasizing their role in enhancing tumor detection and staging. Through case studies, Dr. Coakley demonstrates the efficacy of high-quality MRI in identifying clinically significant cancers that were missed by traditional methods. Data supporting targeted-only biopsies for positive MRI findings are presented, with discussions on the low yield and increased complications of systematic sampling. Dr. Coakley challenges conventional views on multifocality and secondary foci, showing minimal impact on prognosis. He urges the adoption of advanced MRI-guided techniques while acknowledging the need for further research. This insightful presentation invites viewers to explore evolving strategies in prostate cancer diagnostics and their implications for patient outcomes.

Leveraging Big Data in Surgery through HL7 Integration and Computer Vision

Archan Khandekar, MD | Nov 2024

Archan Khandekar, MD, delivers a compelling presentation on integrating Big Data into surgery. The 10-minute talk explores the evolution of healthcare data, from adopting electronic health records to cutting-edge technologies like computer vision and AI-driven surgical assistance.

Dr. Khandekar highlights how traditional data sources such as labs and medical histories are now complemented by innovative tools like operative videos and robotic kinematic data. He delves into the transformative role of AI in enhancing surgical workflow, predicting outcomes, and improving documentation accuracy. He includes real-world applications, such as using computer vision to calculate ischemia times and integrating data from diverse sources to scale analytics for large populations.

Challenges, including data privacy, user adoption, and system integration, are addressed alongside ethical considerations in AI implementation. With a forward-looking perspective, Dr. Khandekar envisions a future where AI supports real-time intraoperative guidance and skill assessment.

Results from the Norwegian Prostate Cancer Consortium (NPCC)

Jan Oldenburg, MD, PhD | Nov 2024

Jan Oldenburg, MD, PhD, presents a detailed exploration of findings from the Norwegian Prostate Cancer Consortium, focusing on the predictive value of baseline PSA levels for prostate cancer risk and mortality. In this 10-minute presentation, Dr. Oldenburg analyzes the data from the NPCC study, revealing that PSA levels strongly correlate with long-term outcomes over an 18-year follow-up period.

Dr. Oldenburg calls for tailored screening protocols to balance early detection with minimizing unnecessary interventions. With comprehensive data and practical implications, his talk offers critical insights into PSA screening, making it an essential watch for clinicians focused on advancing prostate cancer management.